There are no approved drugs and no approved vaccine for Bundibugyo ebolavirus. There are six species in the Ebola genus. Inmazeb (atoltivimab/maftivimab/odesivimab, Regeneron) and Ebanga (ansuvimab, Ridgeback Biotherapeutics) are the two monoclonal-antibody therapies approved by the US Food and Drug Administration. Both target Zaire ebolavirus only1. Neither has demonstrated cross-protection against Bundibugyo in licensure data. The Ervebo vaccine used in the 2018 DRC Equateur response, developed by Merck, is also Zaire-specific. Doctors in Bunia and Mongbwalu have intravenous fluids, isolation rooms and oral rehydration salts: the same toolkit as 1976, when Filovirus was first identified at Yambuku.
WHO's Q1 2026 Blueprint update had flagged exactly this category three months earlier. Maria Van Kerkhove's species-conditional readiness statement is the operational consequence: Bundibugyo falls outside the vaccine conditional. Ebola monoclonals are species-specific because they target the viral glycoprotein, which differs between Zaire, Bundibugyo, Sudan, Reston, Tai Forest and Bombali. Pan-ebolavirus broadly-neutralising antibody work is active in preclinical stages, but no candidate has entered the clinical phase of evaluation for Bundibugyo. Regeneron's REGN3479 component shows preclinical cross-neutralisation but is not approved as a standalone therapy.
Nahid Bhadelia, the infectious-disease physician who ran the Special Pathogens Unit at Boston Medical Center, told a panel of seven Ebola-veteran specialists on Friday 15 May that ribavirin from PALM, the 2018 DRC randomised trial that established Inmazeb and Ebanga, remains the only candidate therapeutic with any cross-Ebola signal worth running labs for, and only where the receiving facility can monitor hepatic function safely2. The pipeline economics behind the gap are visible elsewhere: CEPI and Moderna's Phase 3 H5N1 mRNA trial shows where the resources have been flowing, toward the likeliest pandemic threat by volume of prior investment, not toward non-Zaire Ebola species that have produced three small outbreaks combined before this one. The unresolved PABS vaccine-sharing annex means that even if cross-reactivity data emerged tomorrow, no settled multilateral framework would govern equitable distribution into Ituri.
